10,11-DIHYDRO-N,N-DIMETHYL-5H-DIBENZO(A,D)CYCLOHEPTENE-DELTA5,GAMMA-PROPYLAMINE N-OXIDE
Major Depressive Disorder
HolsboerMaschmeyer NeuroChemie GmbHSmall moleculePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 89/ 100
Competitive context
235 Active assets in the Major Depressive Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Zelapar Corium Innovations, Inc. | Phase 4 | BBB |
Risperdal Johns Hopkins University | Phase 4 | BBB |
EDIVOXETINE Eli Lilly and Company | Phase 3 | BBB |
Vortioxetine Mayo Clinic | Phase 4 | BBB |
Opc-34712 Nova Scotia Health Authority | Phase 4 | BBB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →